| P50 | author | Kazunori Imada | Q67544471 |
| P2093 | author name string | Minako Mori | |
| | Akihito Yonezawa | |
| | Takashi Onaka | |
| | Tomoya Kitagawa | |
| | Yuya Sasaki | |
| | Yoshimori An | |
| | Kenji Ando | |
| | Tadaaki Yokota | |
| | Kenichiro Murata | |
| | Oju Katayama | |
| P2860 | cites work | A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. | Q44254874 |
| | Current treatment in cardiac amyloidosis | Q46141603 |
| | Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis | Q47861129 |
| | Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. | Q50622497 |
| | Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. | Q54269247 |
| | Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio | Q57217547 |
| | CyBorD: stellar response rates in AL amyloidosis | Q58030057 |
| | Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival | Q58853078 |
| | Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study | Q33920664 |
| | Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques | Q34392552 |
| | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. | Q34437074 |
| | Diagnosis and management of the cardiac amyloidoses | Q34454122 |
| | Relationship between monoclonal gammopathy and cardiac amyloid type. | Q34458686 |
| | Current trends in diagnosis and management of cardiac amyloidosis | Q34556410 |
| | Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements | Q36910372 |
| | (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses | Q37054790 |
| | Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis | Q37186950 |
| | Amyloid diseases of the heart: assessment, diagnosis, and referral | Q37819545 |
| | Investigation of the freely available easy-to-use software 'EZR' for medical statistics | Q41513106 |
| | Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. | Q43050098 |
| | Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis | Q44248482 |
| P433 | issue | 11 | |
| P921 | main subject | echocardiography | Q216933 |
| P304 | page(s) | 1885-1890 | |
| P577 | publication date | 2015-08-08 | |
| P1433 | published in | Annals of Hematology | Q15766509 |
| P1476 | title | Clinical and echocardiographic characteristics for differentiating between transthyretin-related and light-chain cardiac amyloidoses | |
| P478 | volume | 94 | |